Innate Pharma raises euro 20 million in its second round of financing
Innate Pharma and Novo Nordisk A/S sign licensing deal
Innate Pharma strenghtens its management team with the recruitment of S.Boissel as CFO
Frank Morich joins Innate Pharma's board of Directors
Innate Pharma obtains ISO9001:2000 certification for its research and development activities in the field of immunotherapy
Innate Pharma announces the achievement of the first milestone in its collaboration with Novo Nordisk A/S
Innate Pharma welcomes Dr. Squiban as Chief Medical Officer
Financial calendar for 2008 and update on next meetings with analysts and investors
IPH 2201, a novel monoclonal antibody targeting NK cells, enters into regulatory pre-clinical development
Turnover of 5.1 million euros for the first nine months of 2007
